CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Varex Equity	Total Varex Equity Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Shares outstanding, beginning of period (in shares) at Sep. 28, 2018					38,000,000.0
Balance at beginning of period at Sep. 28, 2018	$ 428.3		$ 426.2		$ 0.4	$ 357.6	$ 5.8	$ 62.4		$ 2.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	15.3		15.5					15.5		(0.2)
Exercise of stock options (in shares)					0
Exercise of stock options	0.8		0.8			0.8
Common stock issued upon vesting of restricted shares (in shares)					200,000
Shares withheld on vesting of restricted stock (in shares)					0
Shares withheld on vesting of restricted stock	(2.1)		(2.1)			(2.1)
Common stock issued under employee stock purchase plan (in shares)					200,000
Common stock issued under employee stock purchase plan	3.8		3.8			3.8
Share-based compensation	11.7		11.7			11.7
Unrealized gain on interest rate swap contracts, net of tax	(6.2)		(6.2)				(6.2)
Unrealized loss on defined benefit obligations, net of tax	(1.3)		(1.3)				(1.3)
Noncontrolling interest acquired/consolidated	1.4									1.4
Shares outstanding, end of period (in shares) at Sep. 27, 2019					38,400,000
Ending balance at Sep. 27, 2019	448.2	$ (3.5)	444.9	$ (3.5)	$ 0.4	371.8	(1.7)	74.4	$ (3.5)	3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	(57.9)		(57.9)					(57.9)		0.0
Exercise of stock options (in shares)					100,000
Exercise of stock options	1.5		1.5			1.5
Common stock issued upon vesting of restricted shares (in shares)					200,000
Shares withheld on vesting of restricted stock (in shares)					(100,000)
Shares withheld on vesting of restricted stock	(1.8)		(1.8)			(1.8)
Common stock issued under employee stock purchase plan (in shares)					200,000
Common stock issued under employee stock purchase plan	3.6		3.6			3.6
Share-based compensation	13.4		13.4			13.4
Unrealized gain on interest rate swap contracts, net of tax	0.4		0.4				0.4
Unrealized loss on defined benefit obligations, net of tax	0.6		0.6				0.6
Conversion feature of Convertible Notes, net of issuance costs	49.7		49.7			49.7
Purchase of hedges	(61.0)		(61.0)			(61.0)
Issuance of warrants	49.8		49.8			49.8
Foreign currency translation adjustments	1.5		1.5				1.5
Shares issued to settle deferred compensation (in shares)					300,000
Shares issued to settle deferred consideration	7.4		7.4			7.4
Reclassification from mezzanine equity to equity for noncontrolling interest in MeVis Medical Solutions, AG	11.3									11.3
Other	$ (0.6)		(0.1)					(0.1)		(0.5)
Shares outstanding, end of period (in shares) at Oct. 02, 2020	39,059,094				39,100,000
Ending balance at Oct. 02, 2020	$ 465.8	$ (0.3)	451.7	$ (0.3)	$ 0.4	434.4	0.8	16.1	$ (0.3)	14.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	17.9		17.4					17.4		0.5
Common stock issued upon vesting of restricted shares (in shares)					200,000
Shares withheld on vesting of restricted stock (in shares)					(100,000)
Shares withheld on vesting of restricted stock	(1.5)		(1.5)			(1.5)
Common stock issued under employee stock purchase plan (in shares)					200,000
Common stock issued under employee stock purchase plan	2.8		2.8			2.8
Share-based compensation	13.9		13.9			13.9
Unrealized gain on interest rate swap contracts, net of tax	0.0
Unrealized loss on defined benefit obligations, net of tax	(0.1)		(0.1)				(0.1)
Foreign currency translation adjustments	(0.7)		(0.7)				(0.7)
Reclassification from mezzanine equity to equity for noncontrolling interest in MeVis Medical Solutions, AG										0.0
Other	$ (1.6)		(0.2)			(0.2)				(1.4)
Shares outstanding, end of period (in shares) at Oct. 01, 2021	39,435,830				39,400,000
Ending balance at Oct. 01, 2021	$ 496.5		$ 483.3		$ 0.4	$ 449.4	$ 0.0	$ 33.5		$ 13.2